Anavex Life Sciences Corp (AVXL)

[crescentmotor]

Interim share price of a manipulated clinical stage biotech is immaterial.

Maybe it goes without saying, but that is only true in the very narrow context where a low share price is followed by Rett and/or AD success. Otherwise, it is extremely material in the face of potential failure in the case where a stockholder has a material portion of his wealth invested in a stock. It's like the saying we hear all the time that unrealized losses in the stock market don't count unless you have sold a stock realizing those losses. They, of course, do count because individual stockholder equity has been destroyed and there is no assurance it will be recouped.